Cholesterol: enhancing stability and efficacy in lipid-based drug delivery
Download our latest whitepaper to learn how cholesterol can enhance stability and efficacy in lipid-based drug delivery.
As versatile formulations with a range of administration routes, lipid based drug delivery systems (LBBDS) have gained significant attention in pharmaceutical research. Offering a range of benefits including API solubility and bioavailability, LBBDS can be tailored to meet your formulation requirements. Cholesterol is a key component of LBDDS, providing structural support, in addition to such as benefits such as enhanced gene transfection.
Whitepaper: Cholesterol - enhancing stability and efficacy in lipid-based drug delivery
![Cholesterol: enhancing stability and efficacy in lipid-based drug delivery whitepaper](/mediaassets/images/health-care/health-care-new-website/literature/cholesterol-whitepaper-cover.jpg?w=500&la=en-GB&focalpointcrop=1&xratio=105&yratio=140&hash=05087A57E8100145CE0E5E33A629E447)
![avanti polar lipids logo](/mediaassets/images/health-care/health-care-new-website/png/black-green-avanti-logo.png?h=319&iar=0&w=768&la=en-GB&hash=FF2902CD5F1EAF8423AF298E07FD17DD)
Avanti - highly specialised and custom lipids
Avanti Polar Lipids develops high-purity, polar lipids that are being used as delivery systems for complex therapeutic drugs and in next-generation mRNA vaccines. These are highly specialised lipids used in Lipid Nanoparticle (LNP) delivery technology, with a vast portfolio of phospholipids, cationic lipids, PEG lipids and sterols.
Avanti has a formulations division to develop custom lipid-based drug delivery systems for a range of pharmaceutical applications, with vast expertise on development and scale-up and manufacturing of lipids under cGMP.